Modifying gap junction communication in cancer therapy.
Antineoplastic Agents
/ administration & dosage
Apoptosis
/ drug effects
Cadherins
/ drug effects
Cell Communication
/ drug effects
Cell Line, Tumor
Cell Membrane
/ drug effects
Connexins
/ drug effects
Dexamethasone
/ administration & dosage
Ganciclovir
/ administration & dosage
Gap Junctions
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
HeLa Cells
Histone Deacetylase Inhibitors
/ administration & dosage
Humans
Molecular Targeted Therapy
/ methods
Neoplasms
/ drug therapy
Tretinoin
/ administration & dosage
Valproic Acid
/ administration & dosage
ATRA
Connexins
Dexamethasone in prodrug activation therapy
HDAC inhibitors
Prodrug activation therapy
Journal
Current research in translational medicine
ISSN: 2452-3186
Titre abrégé: Curr Res Transl Med
Pays: France
ID NLM: 101681234
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
22
05
2020
revised:
07
08
2020
accepted:
22
09
2020
pubmed:
19
10
2020
medline:
22
12
2021
entrez:
18
10
2020
Statut:
ppublish
Résumé
Drug delivery is crucial for therapeutic efficacy and gap junction communication channels (GJIC) facilitate movement within the tumour. Pro-drug activation, a modality of cancer therapy leads to Ganciclovir triphosphate (GCV-TP) incorporation into newly synthesized DNA resulting in cell death. The objective was to enhance, with Histone deacetylase inhibitors (HDACi) and All Trans Retinoic Acid (ATRA), GJIC, crucial for drug delivery, and with combination, abrogate the observed detrimental effect of Dexamethasone (DXM). Cell lines (NT8E, and HeLa) were pre-treated with Valproic Acid (VPA) (1 mM), 4 Phenyl Butyrate (4PB) (2 mM), ATRA (10 μM) and Dexamethasone (1 μM). Protein quantitated with the Bicinchoninic (BCA) assay for cell lysates, membrane and soluble fractions was assessed with Western blotting for Connexins (43, 26 and 32) and E-Cadherin. A qRT-PCR was done for CX 43-GJA1, CX 26-GJB2, CX 32-GJB1 and E-Cadherin, and normalized with Glyceraldehyde Phosphate dehydrogenase (GAPDH). Further, localization of Connexins (CX) and E-Cadherin, GJIC competence, pre-clinical in-vitro studies and the mechanism of cell death were evaluated. There was no toxicity or change in growth patterns observed with the drugs. In both the cell lines CX 43 localized to the membrane whereas CX 32 and CX 26 were present but not membrane bound. E-Cadherin was present on the membrane in NT8E and completely absent in HeLa cells. Effects of HDACi, DXM and ATRA were seen on the expression of Connexins and E-Cadherin in both the cell lines. NT8E and HeLa cell lines showed enhanced GJIC with 4PB [30 %], VPA [36 %] and ATRA [54 %] with a 60 % increase in cytotoxicity and an abrogation of Dexamethasone inhibition on combination with VPA or ATRA. An enhancement of GJIC function by HDACi and ATRA increased cytotoxicity and could be effective in the presence of Dexamethasone, when combined with ATRA or VPA.
Identifiants
pubmed: 33069641
pii: S2452-3186(20)30057-X
doi: 10.1016/j.retram.2020.09.002
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Cadherins
0
Connexins
0
Histone Deacetylase Inhibitors
0
ganciclovir triphosphate
0
Tretinoin
5688UTC01R
Valproic Acid
614OI1Z5WI
Dexamethasone
7S5I7G3JQL
Ganciclovir
P9G3CKZ4P5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103268Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.